Recommend Limiting Dose and Duration of NSAIDs in High-CV-Risk Patients

January 2017

Controversy will continue to brew over the safety of NSAIDs in patients at high cardiovascular risk.

Most NSAIDs have a warning about increased risk of CV events.

But the thinking has been that CV risk varies...with celecoxib (Celebrex, etc) being more risky and naproxen the least.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology Recommend Limiting Dose and Duration of NSAIDs in High-CV-Risk Patients
Lice Dispel Myths About Treating Head Lice
Opioids Be Ready to Help More Patients Use Buprenorphine/Naloxone
Vaccines Offer Prevnar 13 to All Healthy Older Adults
Vaccines Consider Which Pregnant Women Need Pertussis Vaccine
Inhalers Prevent Common Inhaler Errors
Calcium Help Patients Use Calcium Supplements Safely
Pediatrics Suggest Systemic Quinolones Only Rarely in Kids...But Not Due to Joint Concerns
Dehydration Consider Diluted Apple Juice an Option for Mild Dehydration in Kids
End-of-Life Care Provide Options to Enhance End-of-Life Care
Biosimilars Recommend the New Biosimilar Brenzys as a Cheaper Alternative to Enbrel
Insurance Prioritize Urgent Prior Auth Requests to Avoid Gaps in Therapy